Blood consult: treating del(5q) myelodysplastic syndromes.

A 58-year-old man with a past medical history of underlying congenital aortic valve defect and hypertension was incidentally diagnosed with an isolated anemia (hemoglobin of 7.8 g/dL) when he presented to his cardiologist with symptoms of fatigue and exertional dyspnea. Evaluation for common causes

[1]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[2]  Eva Hellström-Lindberg,et al.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. McDevitt,et al.  Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. , 2011, Blood.

[4]  P. Woll,et al.  Persistent malignant stem cells in del(5q) myelodysplasia in remission. , 2010, The New England journal of medicine.

[5]  R. Schlenk,et al.  Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q). , 2009 .

[6]  J. Byrd,et al.  A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide , 2009, Proceedings of the National Academy of Sciences.

[7]  J. Maciejewski,et al.  Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Kantarjian,et al.  Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. , 2008, Journal of the National Cancer Institute.

[9]  M. Sekeres,et al.  Active Treatment Strategies Improving Outcomes in Patients with Myelodysplastic Syndromes with the Deletion 5q Abnormality , 2008 .

[10]  T. Golub,et al.  Identification of RPS14 as a 5q- syndrome gene by RNA interference screen , 2007, Nature.

[11]  M. Gordon.  Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .

[12]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[13]  A. Kasprzyk,et al.  Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. , 2002, Blood.